Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma

The development of BRAF and MEK inhibitors (BRAFi/MEKi) has led to major advances in melanoma treatment. However, the emergence of resistance mechanisms limits the benefit duration and a complete response occurs in less than 20% of patients receiving BRAFi ± MEKi. In this study, we evaluated the imp...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Transl Oncol
Huvudupphovsmän: Reger de Moura, Coralie, Vercellino, Laetitia, Jouenne, Fanélie, Baroudjian, Barouyr, Sadoux, Aurélie, Louveau, Baptiste, Delyon, Julie, Serror, Kevin, Goldwirt, Lauriane, Merlet, Pascal, Bouquet, Fanny, Battistella, Maxime, Lebbé, Céleste, Mourah, Samia
Materialtyp: Artigo
Språk:Inglês
Publicerad: Neoplasia Press 2019
Ämnen:
Original article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6931208/
https://ncbi.nlm.nih.gov/pubmed/31874374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.10.003
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk